Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

Dr. Garon, Associate Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center, Geffen School of Medicine, University of California, Los Angeles, explains the role of biomarkers, PD-L1 and TMB in identifying those lung cancer patients most likely to benefit from therapies

Edward B. Garon, MD, elaborates on the role of PD-L1 in the management of lung cancer

Dr. Garon on Antiangiogenic Agents in Lung Cancer

Dr. Edward Garon—Connecting for Lung Cancer Cures

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial

Dr. Garon on Future of Immunotherapy in NSCLC

Edward Garon MD, expounds on the new FDA approval of erlotinib + ramuciramab in EGFR positive aNSCLC

Problems with PD-L1 expression testing in patients with NSCLC

A Discussion on Immune Checkpoint Inhibitors in Lung Cancer

Dr. O’Donnell on Challenges With PD-L1 Testing in Bladder Cancer

Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

Improving the SOC for ALL with inotuzumab

Chemoimmunotherapy for bladder cancer: similarties to lung cancer